AND017
Stories
-
Kind Pharmaceuticals registers Phase 3 study of AND017 in NDD-CKD anemia
The study, led by Kind Pharmaceuticals LLC, plans to enroll 240 participants and begin in February 2027. It compares AND017 capsules with erythropoietin stimulating agents in non-dialysis-dependent chronic kidney disease patients with anemia.